Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could ...
Pharmaceutics . 2020 Sep 30;12(10):937. doi: 10.3390/pharmaceutics12100937 Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR Elodie Pothin Elodie Pothin 1 Antibody Engineering Platform, Structural Biology and Chemistry Department, Institut Pasteur, 75015 Paris, France; elodie.pothin@pasteur.fr 2 Tissue Barriers, Rare and Neurological Diseases TA Department, Sanofi, 91161 Chilly-Mazarin, France Find articles by Elodie Pothin 1, 2 , Dominique Lesuisse Dominique Lesuisse 2 Tissue Barriers, Rare and Neurological Diseases TA Department, Sanofi, 91161 Chilly-Mazarin, France Find ar
related reading
- Cellular and signalling mechanisms that regulate the blood–brain barriernature.com
- Gap Mapgap-map.org
- Neurotechnology Numbers Worth Knowingmilan.cvitkovic.net
- Mesa — JURA Bio, Inc.jura.bio
- A heart of firemarleyx.com
- In vitro-engineered non-antibody protein therapeuticsncbi.nlm.nih.gov
- An underleveraged modality in neuroscience | Abhi Upadhyayaxu.sh
- High-throughput measurements of protein domain functions using magnetic separation - PubMedpubmed.ncbi.nlm.nih.gov
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- RNA Interference–Based Therapy and Its Delivery Systemsncbi.nlm.nih.gov
- Manifold Bio | Tissue-targeted medicines, designed in vivomanifold.bio
- Engineered serum markers for non-invasive monitoring of gene expression in the brain | Nature Biotechnologynature.com